MADRID--(BUSINESS WIRE)--Bioiberica confirms, once again, their presence at CPhI Worldwide, the most important event for producers of pharmaceutical ingredients and solutions. At this year’s edition, held 9 – 11 October in Madrid, Spain, the exhibition will be attended by more than 2500 exhibitors from 150 countries as well as more than 45,000 professionals of the pharmaceutical sector.
At booth 14.0F40, Bioiberica’s Heparin Science and Health Care Divisions will be presenting new animal-derived APIs. These include thyroid extract (rich in T-3 and T-4 hormones and obtained through natural methods) and calcium heparin, as well as other biological products currently under development, such as trypsin and others.
Bioiberica is a pharmaceutical company of global reach, specializing in the identification and extraction of biomolecules of animal origin of high biological and therapeutic value for the pharma and nutraceutical industry. It is a world leader in the production of the pharmaceutical-grade active ingredient of heparin. Their large portfolio also includes sodium, lithium, calcium and ammonic heparin, dermatan sulfate, heparan sulfate, and heparinoids.
The company is also a leader in pharmaceutical-grade active ingredients and finished products for joint health and mobility, such as chondroitin sulfate, glucosamine, hyaluronic acid and native collagen. More precisely, this year stands out b-2Cool®, a natural ingredient which helps maintain joint health thanks to its immune mediated mechanism of action. And, among the finished products portfolio, the highlight will be Hialsorb® Intraarticular, an injectable hyaluronic acid.
For Bioiberica, this event represents a unique occasion to identify business opportunities and forge new partnerships. It also provides a unique occasion to learn about the latest market trends and developments.
